Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

Clinical trial NCT06889688 · RECRUITING

Trial details

NCT number: NCT06889688
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Cancer Stage IV Triple -Negative Breast Cancer

Start date: 2025-02-21
Primary completion: 2028-12-31
Enrollment: 246

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.